Please note that this information is specific to the UK and is not intended to replace the advice of a qualified healthcare professional. Chugai Pharma Europe Ltd and Chugai Pharma UK Ltd are unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
To report an Adverse Reaction directly to Chugai Pharma Europe Ltd or Roche Products Ltd, please click below. Details for Chugai Pharma Europe Ltd are also available at the bottom of this page.
Akynzeo® (palonosetron/netupitant) Hard Capsules
Helsinn is the marketing authorisation holder for Akynzeo and Chugai in Europe work closely in partnership with Helsinn to promote this medicine to prescribers.
Aloxi® (palonosetron) Solution for Injection
Helsinn is the marketing authorisation holder for Aloxi and Chugai in Europe work closely in partnership with Helsinn to promote this medicine to prescribers.
Granocyte® (lenograstim) 13 million IU/mL Powder and Solvent for Solution for Injection/Infusion
Granocyte® (lenograstim) 34 million IU/mL Powder and Solvent for Solution for Injection/Infusion
Hemlibra® (emicizumab) 30 mg/mL Solution for Injection
Roche is the GB/NI marketing authorisation holder for Hemlibra. Chugai in Europe works with Roche under a co-promotion agreement.
Roche is the GB/NI marketing authorisation holder for Hemlibra. Chugai in Europe works with Roche under a co-promotion agreement.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Chugai Pharma Europe Ltd using the details below. To report an adverse event to Roche Products Ltd (for Hemlibra), please see the details here.
Report an Adverse Reaction to Chugai Pharma Europe Ltd
(for Akynzeo, Aloxi and Granocyte)
Telephone: +44 (0) 20 8987 5600
Email: [email protected]
Roche is the GB/NI marketing authorisation holder for Hemlibra. Chugai in Europe works with Roche under a co-promotion agreement.
Helsinn is the marketing authorisation holder for Akynzeo and Aloxi, and Chugai in Europe work closely in partnership with Helsinn to promote these medicines to prescribers.
C-GB-00000898 | Date of Preparation: December 2023
Chugai Pharma Europe Ltd takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharma Europe Ltd will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following “Privacy Statement” and “Important Information.”
Copyright © 2023 Chugai Pharma Europe Ltd. All rights reserved.
